News

Boehringer Ingelheim and 3T Biosciences, announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to…
Read More...

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced that it has signed a multi-year research collaboration and option…
Read More...

Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), announced the signing of…
Read More...

AstraZeneca’s Biologics License Application (BLA) for nirsevimab has been accepted for review by the US Food and Drug Administration (FDA) for the prevention of respiratory syncytial…
Read More...

Adcendo ApS, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces a license agreement with…
Read More...

Eisai Co., Ltd. and Biogen Inc. announced that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb (Brand Name in the U.S.:…
Read More...

AbbVie and Immunome, Inc. announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor…
Read More...

Moderna, Inc. and CytomX Therapeutics, Inc. announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's…
Read More...

Moderna, Inc. and OriCiro Genomics K.K. announced they have entered into a definitive agreement through which Moderna will acquire OriCiro for $85 million. "With this acquisition, we…
Read More...

Orbit Discovery Limited (Orbit) announced it has entered into a Master Service Agreement with SanegeneBio Inc., (Sanegene), a start-up company dedicated to developing novel RNAi-based…
Read More...

Shanghai Xianbo Biotech Co., Ltd., also known as Simnova outside of China, an affiliate of Simcere Investment Group and a clinical-stage biotechnology company developing proprietary…
Read More...

AmerisourceBergen Corporation announced the completion of its acquisition of PharmaLex Holding GmbH. The acquisition of PharmaLex enhances AmerisourceBergen’s growth strategy by…
Read More...

Alpha Healthcare Acquisition Corp. III, a special purpose acquisition company led by Mr. Rajiv Shukla, announced the execution of a definitive business combination agreement with…
Read More...

Capsida Biotherapeutics Inc. announced a multi-year strategic collaboration with Prevail Therapeutics ("Prevail"), a wholly owned subsidiary of Eli Lilly and Company ("Lilly"), to…
Read More...

Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, announced a multi-year collaboration with…
Read More...

WuXi Biologics announced a license agreement with GSK plc under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi…
Read More...

Transcenta Holding Limited, a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based…
Read More...

MaxCyte, Inc. announced the signing of a strategic platform license (SPL) with Catamaran Bio, Inc., a biotechnology company developing novel, off the-shelf chimeric antigen receptor…
Read More...

Gilead Sciences, Inc. and EVOQ Therapeutics, Inc. (EVOQ) announced a collaboration and licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid…
Read More...

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and Abiosciences, the single-cell bioinformatics leader, announced a new partnership to co-develop…
Read More...